Etripamil Nasal Spray Outperforms Placebo for AFib with Rapid Ventricular Rate

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.

Related Keywords

United Kingdom ,Netherlands ,Canada ,United States ,London ,City Of ,American ,British ,A John Camm , ,American Heart Association Scientific Sessions ,Clinical Sciences Research Institute ,Cardiology Clinical Academic Group ,Milestone Pharmaceuticals Inc ,Milestone Pharmaceuticals ,George University ,British Heart Foundation Emeritus Professor ,Clinical Cardiology ,Revera Phase ,Etripamil ,Etripamil Nasal Spray ,Nasal Spray For Afib ,Atrial Fibrillation ,Afib ,Aha 2023 ,